CD4^LVFOXP3 Treg-like cell therapy

N/A

Report date: 2024/12/18 11:19:33

Base Information

Drug NameCD4^LVFOXP3 Treg-like cell therapy

Drug Alias NameCD4^LVFOXP3

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector

Mechanisms of ActionCell replacementsForkhead box protein P3 gene transference

TargetsForkhead box protein P3

Therapy Area/IndicationsPolyendocrinopathies, Autoimmune

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesStanford University

China Registration ClassN/A

Develop Information

Active CompaniesStanford University

Inactive CompaniesN/A

Active IndicationsPolyendocrinopathies, Autoimmune

Inactive IndicationsN/A

Other Information

ATC CodeN/A